Lumitin (conbercept) / Chengdu Kanghong Pharma - LARVOL DELTA

Investigating Predictors of Retreatment following Initial Antivascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. (PubMed, J Curr Ophthalmol) - "Among children treated with anti-VEGF agents, the highest IR occurred with intravitreal ranibizumab (IVR, 0.25 mg) (27%, 95% CI: 19%-35%) and intravitreal aflibercept (IVA, 0.4 mg) (27%, 95% CI: 6%-47%), followed by intravitreal conbercept (IVC, 0.25 mg) (16%, 95% CI: 13%-20%). The lowest IR was observed in children treated with intravitreal bevacizumab (IVB, 0.625 mg) (11%, 95% CI: 7%-14%)...While anti-VEGF therapy is effective for ROP treatment, there are significant differences in IR among different agents. IVB treatment appears to yield the most consistent results compared to other agents."

Journal • Retrospective data • Review • Retinal Disorders • Retinopathy of Prematurity

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review. (PubMed, Value Health Reg Issues) - "Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. (PubMed, Eur J Pharmacol) - "Aflibercept and conbercept may be preferred when anatomical outcomes are prioritized, whereas faricimab's extended dosing interval could benefit treatment-adherent populations. The superior safety profile of aflibercept 2 mg warrants consideration in risk averse patients. These differential effects support personalized therapeutic decision-making."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Aqueous Humor Proteome in RVO-Associated Macular Edema: Analysis during Three Consecutive Conbercept Treatments. (PubMed, ACS Omega) - "This exploratory proteomic analysis identified distinct pathway alterations in early RVO pathogenesismetabolic in BRVO and inflammatory in CRVOand common treatment-related changes: plasma kallikrein was downregulated, while desmocollin-3 was up-regulated."

Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • FBLN1 • FSTL1

Vitrectomy with Subretinal Tenecteplase and Intravitreal Conbercept for Submacular Hemorrhage: A Prospective Interventional Study. (PubMed, Retina) - "The present technique for treatment-naïve spontaneous SMH, in combination with subretinal TNK-tPA injection, intravitreal conbercept administration, and C3F8 gas tamponade, demonstrated potential for visual improvement in eyes treated within 30 days of SMH onset."

Journal • Age-related Macular Degeneration • Cardiovascular • Hematological Disorders

Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China (ISPOR-EU 2025) - "However, calculation of these drugs' societal value remains unexplored. The societal value of 4 therapies for the diseases from 2024 to 2033 was estimated, which are currently included in the National Reimbursement Drug List (NRDL), namely faricimab, aflibercept, ranibizumab, and conbercept. Intravitreal injections demonstrate great societal value and significant improvement in quality of life for patients with retinal vascular diseases. Our findings further provide a new perspective for the NRDL to assess innovative drugs' value, underscoring the importance of multiple dimensions in the assessment of the value of innovative medication."

Reimbursement • US reimbursement • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Spontaneous remission of retinal capillary macroaneurysm: case report. (PubMed, Front Med (Lausanne)) - "Although the lesion initially enlarged after three intravitreal injections of conbercept, it eventually resolved spontaneously. This outcome suggested that close observation may be appropriate for RCM patients with stable, good vision if such patients are unwilling or afraid to receive laser treatment."

Journal • Cardiovascular • Hematological Disorders • Retinal Disorders • Retinal Vein Occlusion

Analysis of the Efficacy of Conbercept in Treating Macular Neovascularization of Different nAMD Subtypes Based on OCTA Evaluation (ChiCTR) - P=N/A | N=45 | Not yet recruiting | Sponsor: Nanchong Hospital , Affiliated to Beijing Anzhen Hospital, Capital Medical University; Nanchong Hospital , Affiliated to Beijing Anzhen Hospital, Capi

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

A real-world study on the treatment of refractory diabetic macular edema with Conbercept combined with micropulse laser therapy (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University Dezhou Hospital; Qilu Hospital of Shandong University Dezhou Hospital

New trial • Real-world evidence • Diabetes • Diabetic Macular Edema • Macular Edema • Metabolic Disorders • Ophthalmology

Wide-field OCT angiography-guided precise laser therapy for ischemic branch vein occlusion in anti-VEGF era (ChiCTR) - P=N/A | N=50 | Recruiting | Sponsor: Eye and ENT hospital of Fudan University; Eye and ENT hospital of Fudan University

New trial • Retinal Disorders • Retinal Vein Occlusion

Conbercept Treatment for Heart-Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti-VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA. (PubMed, Clin Case Rep) - "Anti-VEGF therapies, such as Aflibercept (Eylea), Bevacizumab (Avastin), Brolucizumab (Beovu), Conbercept (Lumitin), Faricimab (Vabysmo), Ranibizumab (Lucentis), and Pegaptanib (Macugen), have significantly transformed MNV management, targeting VEGF to curb this pathological vascular growth. Conbercept, in particular, proved effective against the complex intertwined nets observed in this patient. These findings emphasize the promise of individualized treatment strategies and the potential of OCTA-based vascular geometry classification as a tool for precision medicine."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetes • Hypertension • Macular Degeneration • Metabolic Disorders • Mood Disorders • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy of intravitreal injection of anti-vascular endothelial growth factor as an adjunctive treatment for proliferative diabetic retinopathy before pars plana vitrectomy: a systematic evaluation and meta-analysis. (PubMed, Int Ophthalmol) - "The preoperative use of anti-VEGF agents in PPV can reduce the incidence of intraoperative VH and retinal tears, thereby facilitating a quicker and easier surgical procedure."

Clinical • Journal • Retrospective data • Review • Diabetic Retinopathy • Hematological Disorders • Ophthalmology • Retinal Disorders

Based on the quantitative analysis of retinal vascular ischemia index (ISI) and aqueous humor cytokines in the "AI-physician" collaboration, the clinical efficacy of Conbercept in the treatment of RVO was evaluated (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: The First People's Hospital of Xuzhou City; The First People's Hospital of Xuzhou City

New P4 trial • Cardiovascular • Retinal Vein Occlusion

Conbercept combined with 577 nm subthreshold micropulse laser for diabetic macular edema. (PubMed, Int J Ophthalmol) - "Conbercept combined with STML has better outcomes for treatment of DME and less intravitreal injections compared to conbercept monotherapy."

Journal • Diabetic Macular Edema • Ophthalmology

Recent advances in the study of Conbercept for diabetic macular edema. (PubMed, Int J Retina Vitreous) - "This systematic review explores the mechanism of action and latest research advancements of Conbercept in DME treatment, integrating clinical trial data and comparisons with other anti-VEGF therapies. It further discusses existing limitations in current research and proposes future research directions."

Journal • Review • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Effect of Adjuvant Conbercept on Patients with Macular Edema Induced by Diabetic Retinopathy and Retinal Vein Occlusion Undergoing Laser Treatment: Impact on Symptom Improvement. (PubMed, Int J Gen Med) - "Adverse event rates did not differ significantly (9.38% vs 12.90%, P>0.05). Conbercept adjunctive to laser therapy in DR- or RVO-related macular edema enhances clinical efficacy, accelerates symptom resolution, improves visual and retinal function, and does not increase adverse reaction risk."

Journal • Diabetic Retinopathy • Hematological Disorders • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Comparative efficacy of subretinal and intravitreal conbercept injections in polypoidal choroidal vasculopathy. (PubMed, Int Ophthalmol) - "Subretinal conbercept provides superior and more durable anatomical and functional outcomes compared to intravitreal injection in patients with PCV. It also reduces treatment burden and enhances lesion regression, supporting its potential as a promising alternative therapeutic approach."

Clinical • Journal • Retrospective data • Age-related Macular Degeneration

Efficacy of Intravitreal Conbercept in Vitrectomy for Proliferative Diabetic Retinopathy: An Integrated Meta-Analysis and Bibliometric Study. (PubMed, Clin Ophthalmol) - "No significant difference was found between Conbercept and Ranibizumab in BCVA or intraoperative outcomes. This systematic review revealed that, similarly to other anti-VEGF injections, Conbercept injection improved BCVA and had lower rates of intraoperative and postoperative complications. Conbercept research shows strong global collaboration and evolving focus on clinical applications in retinal vascular disease management."

Journal • Retrospective data • Review • Cardiovascular • Diabetic Retinopathy • Hematological Disorders • Retinal Disorders

Clinical efficacy of conbercept combined with micropulse laser in patients with polypoidal choroidal vasculopathy. (PubMed, Lasers Med Sci) - "Reductions in VEGF-A and MCP-1 concentrations were positively correlated with improvements in BCVA, CMT, and TMV (P < 0.05). Conbercept combined with MPL therapy demonstrates superior clinical efficacy compared to intravitreal injection of Conbercept alone in patients with PCV. Furthermore, changes in VEGF-A and MCP-1 levels may serve as predictive markers for improvements in visual acuity and retinal morphology in these patients."

Clinical • Journal • Age-related Macular Degeneration • IL5

Invisible warriors: the invisible arsenal of nanotechnology against retinoblastoma. (PubMed, Int J Pharm) - "Furthermore, it underscores the most recent developments, challenges, and potential future developments in the delivery of retinoblastoma medications via nanomedicine. Precision medicine and advanced nanocarriers may improve retinoblastoma therapy outcomes, effects, and patient care."

Journal • Review • Eye Cancer • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor • RB1

Intravitreal Double-Dose Conbercept Injection for the Treatment of Neovascular Age-Related Macular Degeneration: A Pilot Real-Life Clinical Practice Study. (PubMed, Clin Ophthalmol) - P4 | "This study was registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn/, ChiCTR2000029503). Registration date: 03/02/2020."

Clinical • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization. (PubMed, Int J Ophthalmol) - "BCVA gains achieved by the end of our study maintain generally sustained at the 24-mo follow-up. The findings also indicate that ranibizumab and conbercept demonstrate comparable efficacy and safety profiles. Additionally, intravitreal anti-VEGF therapy using 1+PRN regimen, offers certain advantages in both efficacy and cost-effectiveness."

Journal • Ophthalmology

Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection (clinicaltrials.gov) - P=N/A | N=8 | Completed | Sponsor: Bojie Hu

New trial • Diabetic Retinopathy • Retinal Disorders

Pars plana vitrectomy followed by subretinal or intravitreal injection with Conbercept and tissue plasminogen activator for clearance of submacular hemorrhage secondary to idiopathic polypoidal choroidal vasculopathy. (PubMed, Int Ophthalmol) - "Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV."

Journal • Retrospective data • Age-related Macular Degeneration • Hematological Disorders • Retinal Disorders

Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema (clinicaltrials.gov) - P=N/A | N=100 | Active, not recruiting | Sponsor: Tianjin Medical University Eye Hospital

New trial • Cataract • Macular Edema • Ophthalmology • Retinal Vein Occlusion